La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Australian Clinical Labs Résultats passés
Passé contrôle des critères 1/6
Australian Clinical Labs has been growing earnings at an average annual rate of 3.2%, while the Healthcare industry saw earnings declining at 6% annually. Revenues have been growing at an average rate of 3.7% per year. Australian Clinical Labs's return on equity is 9.5%, and it has net margins of 2.3%.
Informations clés
3.2%
Taux de croissance des bénéfices
-17.7%
Taux de croissance du BPA
| Healthcare Croissance de l'industrie | 2.4% |
| Taux de croissance des recettes | 3.7% |
| Rendement des fonds propres | 9.5% |
| Marge nette | 2.3% |
| Prochaine mise à jour des résultats | 29 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt
Jun 20
Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?
Feb 21Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?
Dec 08Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today
Aug 14Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)
Dec 22The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More
Dec 21The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business
Sep 01Ventilation des recettes et des dépenses
Comment Australian Clinical Labs gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 23 | 674 | 15 | 0 | 0 |
| 30 Sep 23 | 686 | 26 | 0 | 0 |
| 30 Jun 23 | 697 | 36 | 0 | 0 |
| 31 Mar 23 | 757 | 55 | 0 | 0 |
| 31 Dec 22 | 818 | 73 | 0 | 0 |
| 30 Sep 22 | 907 | 126 | 0 | 0 |
| 30 Jun 22 | 996 | 178 | 0 | 0 |
| 31 Mar 22 | 931 | 156 | 0 | 0 |
| 31 Dec 21 | 867 | 134 | 0 | 0 |
| 30 Sep 21 | 757 | 97 | 0 | 0 |
| 30 Jun 21 | 647 | 60 | 0 | 0 |
| 31 Mar 21 | 598 | 79 | 0 | 0 |
| 31 Dec 20 | 549 | 98 | 0 | 0 |
| 30 Sep 20 | 520 | 70 | 0 | 0 |
| 30 Jun 20 | 491 | 41 | 0 | 0 |
| 30 Jun 19 | 448 | -11 | 315 | 0 |
| 30 Jun 18 | 379 | -9 | 267 | 0 |
| 30 Jun 17 | 340 | -24 | 252 | 0 |
Des revenus de qualité: ACL has a large one-off loss of A$13.7M impacting its last 12 months of financial results to 31st December, 2023.
Augmentation de la marge bénéficiaire: ACL's current net profit margins (2.3%) are lower than last year (9%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ACL has become profitable over the past 5 years, growing earnings by 3.2% per year.
Accélération de la croissance: ACL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: ACL had negative earnings growth (-79%) over the past year, making it difficult to compare to the Healthcare industry average (-19.1%).
Rendement des fonds propres
ROE élevé: ACL's Return on Equity (9.5%) is considered low.